Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Protocol Amendment History 57 amendments
This ClinicalTrials.gov record has been amended 57 times since 2023-08-15; most recent amendment 2026-03-20.
Status change: Recruiting → Active, Not Recruiting 2025-09-12
Status change: Not Yet Recruiting → Recruiting 2023-09-25
Trial Details
NCT Number NCT06003426
Lead Sponsor Bristol-Myers Squibb
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 1,255 participants
Start Date 2023-09-14
Primary Completion 2026-10-06 (estimated)
Study Completion 2027-06-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-24